The 21st International Congress of Therapeutic Drug Monitoring & Clinical Toxicology 2023 will be held in Oslo from September 24 to 27, 2023. The conference is hosted by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT).
The IATDMCT Congress will bring together world-class scientists and healthcare professionals working in therapeutic drug monitoring and clinical toxicology to provide participating researchers and clinicians with a platform to share their research and experiences in basic clinical and translational pharmacology and clinical toxicology. Participants include: drug analysis experts, clinical pharmacologists, clinical toxicologists, doctors, pharmacists, laboratory chemists, etc.
This conference gathers global drug R&D elites to discuss and promote innovation and development in the field of drug R&D. On this world-famous stage, Dr. Xu Xiuli, CEO of Diagreat Biotech, will be an invited guest and deliver an important presentation on the latest research and development progress of Diagreat Biotech’s TDM (therapeutic drug monitoring). Dr. Xu’s presentation will comprehensively demonstrate Diagreat Biotech’s breakthroughs and innovations in the field of TDM. In the presentation, she will explain in simple terms how Diagreat Biotech's unique R&D team breaks the rules and provides personalized and precise medical services through technological innovation and product development, thereby improving medical quality and efficiency.
As a professional biotechnology company, Diagreat Biotech has been committed to developing more leading medical technologies to bring more good news to patients around the world. In this presentation, Dr. Xu will also share the detection technology regarding to the automated Therapeutic Drug Monitoring platform for both chemical pharmaceuticals and biopharmaceuticals from Diagreat Biotech, which solves the clinical pain point of being unable to detect TDM of chemical pharmaceuticals and biopharmaceuticals on the same platform in the past. The chemiluminescence platform uses SDC directional coupling technology toachieve stable results and small batch-to-batch differences in product characteristics. At the same time, Diagreat Biotech expects to launch 36 chemical pharmaceutical drugs, 14 biopharmaceutical drugs and more than 50 conventional items within 2-3 years, and ultimately realize more than 100 chemiluminescence solutions.
The development of the TDM field requires global joint efforts, and we look forward to sharing the results in this field with more partners to provide more and better treatment options for patients around the world. Dr. Xu said in an interview before the conference, 'I am very much looking forward to this presentation showing everyone the strength and potential of Diagreat Biotech in the field of TDM. I also hope to take this opportunity to establish contact with more partners and jointly promote the development of the TDM field.'
Let us look forward to Dr. Xu’s wonderful presentation at the IATDMCT International Academic Conference, witness Diagreat Biotech’s breakthroughs and innovations in the field of TDM, and contribute to the global medical and health industry!
The International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) was established in 1990 and is the only international organization in the world dedicated to promoting the development of global therapeutic drug monitoring and clinical toxicology related disciplines. It is composed of scientists and clinicians from more than 70 countries around the world. The aims of IATDMCT are to promote and enhance education and research in therapeutic drug monitoring and clinical toxicology; improve the practice and clinical interpretation standards of drug and toxic substance analysis and promote the transmission of interpretation through clinical pharmacokinetics and toxicokinetic to enhance patient care; encourage collaboration among members of all professions related to therapeutic drug monitoring and clinical toxicology; encourage the effective application of therapeutic drug monitoring to optimize clinical drug use and maximize clinical and economic benefits; support advances in clinical toxicology as diagnostic tools and therapeutic adjuncts in the treatment of drug overdose, substance abuse, and exposure to environmental toxicants.